Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | CBX7 | O95931 | 2/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1071086 | 0.99 | PRKCA (0.42) | PRKCAMMP12CBX7CDYL2CDYL | |
| SCHEMBL5442324 | 0.91 | PRKCA (0.42) | PRKCAMMP12CBX7CDYL2CDYL | |
| SCHEMBL5436725 | 0.86 | CYP3A4 (0.40) | PRKCAMMP12TACR1CYP3A4CYP2C19 | |
| SCHEMBL5452200 | 0.86 | EGFR (0.43) | PRKCAMMP12TACR1CYP3A4CYP2C19 | |
| SCHEMBL5439087 | 0.85 | TACR1 (0.45) | PRKCAMMP12TACR1CYP3A4CYP2C19 | |
| SCHEMBL5446231 | 0.85 | KMT2A (0.42) | PRKCAMMP12TACR1CYP3A4CYP2C19 | |
| SCHEMBL5433925 | 0.82 | PRKCA (0.44) | PRKCAMMP12CYP3A4CYP2C19NR1H4 | |
| SCHEMBL5438993 | 0.81 | TACR1 (0.40) | PRKCAMMP12TACR1CYP3A4CYP2C19 | |
| SCHEMBL5454107 | 0.80 | PRKCA (0.42) | PRKCAMMP12CDYLCDY1; CDY1BMCHR1 | |
| SCHEMBL5223193 | 0.80 | PRKCA (0.37) | PRKCAMMP12CBX7CDYL2CDYL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101173-A1 | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein | Vivalis (FR) | 2009-09-16 | — | — | EP | claimed |
| WO-2008127613-A1 | NEW PHARMACEUTICAL COMPOSITIONS | SCYNEXIS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | claimed |
| US-20120295843-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295843-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2494991-A1 | Combination therapy for the treatment of HCV infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8258116-B2 | Combination therapy for the treatment of HCV infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258116-B2 | Combination therapy for the treatment of HCV infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2142215-B1 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100172866-A1 | Combination Therapy for the Treatment of HCV Infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100172866-A1 | Combination Therapy for the Treatment of HCV Infection | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2008137126-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008127613-A1 | NEW PHARMACEUTICAL COMPOSITIONS | SCYNEXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127613-A1 | NEW PHARMACEUTICAL COMPOSITIONS | SCYNEXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | NSUN2, TPMT, EIF5B | PRKCA 3523/4885MMP12 4707/4885CBX7 3534/4885 |
| US-20100172866-A1 | Combination Therapy for the Treatment of HCV Infection | SERPINB1, ENPEP, PREP | PRKCA 2448/4885MMP12 125/4885CBX7 1322/4885 |
| US-20120295843-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION | SERPINB1, ENPEP, PREP | PRKCA 2448/4885MMP12 125/4885CBX7 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.